Kenneth S. Santone

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

37

H-Index

1

About

Kenneth S. Santone is a pharmaceutical scientist whose work has advanced the early-stage profiling of drug candidates, particularly in the critical area of metabolic stability. His key research focuses on developing high-throughput analytical methods to predict how potential therapeutics are processed in the body, a vital step in reducing late-stage drug attrition. Santone’s most notable contribution is the creation of the "MetFast assay," an automated liquid chromatography–mass spectrometry (LC-MS) process described in his highly cited 2007 paper. This method allows for the rapid, in vitro assessment of a compound’s susceptibility to cytochrome P450-mediated first-pass metabolism, enabling researchers to quickly identify and prioritize drug candidates with favorable pharmacokinetic profiles. By streamlining this essential screening step, Santone’s work has helped pharmaceutical teams make more informed decisions earlier in the discovery pipeline. His contributions are foundational for scientists and students in drug metabolism and pharmaceutical profiling, demonstrating how efficient, automated techniques can accelerate the journey from lead compound to viable therapy.

Research Focus

Key Achievements

1
H-Index
1
Papers
37
Total Citations
37
Avg Citations/Paper
🏆 Most Cited Paper
An Automated High Throughput Liquid Chromatography–Mass Spectrometry Process to Assess the Metabolic Stability of Drug Candidates
37 citations · 2007
📈 Most Prolific Year: 2007 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago